DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma
NCT ID: NCT01924156
Last Updated: 2016-02-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
30 participants
INTERVENTIONAL
2013-07-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma
NCT00862303
DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating
NCT02487550
DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML
NCT01898663
DC Vaccine Combined With CIK Cells in Patients With SCLC
NCT02688673
DC Vaccine Combined With CIK Cells in Patients With Esophagus Cancer
NCT02693236
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
adenovirus-transfected DC + CIK
adenovirus-transfected autologous DC vaccine plus CIK cells
adenovirus-transfected DC + CIK
adenovirus-transfected DC vaccine plus CIK cells
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
adenovirus-transfected DC + CIK
adenovirus-transfected DC vaccine plus CIK cells
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histopathologically confirmed diagnosis of renal cell carcinoma
* Received standardized treatment of renal cell carcinoma
* Interval between the last standardized treatment and DC/CIK treatment ≥ 4weeks
* KPS (Karnofsky performance scale) \>60
* Patient's written informed consent
* Predicted survival \>3 months
* No severe viral or bacterial infections
Exclusion Criteria
* Patients with other malignancies and infectious diseases
* Pregnant and breast-feeding patient
* Currently participating in another clinical trial
* Unfit for participating in this clinical trial in investigators' opinions
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Affiliated Hospital to Academy of Military Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hu Chen, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Affiliated Hospital to Academy of Military Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Hematopoietic Stem Cell Transplantation
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wang D, Zhang B, Gao H, Ding G, Wu Q, Zhang J, Liao L, Chen H. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer. 2014 Apr 10;14:251. doi: 10.1186/1471-2407-14-251.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
307-CTC-DC/CIK-RCC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.